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ABSTRACT

Background Alzheimer disease includes plaques consisting of aggregates of amyloid
beta (Ap). AP is the product of abnormal cleavage of amyloid precursor protein (APP) by
the secretases P-APP cleaving enzyme-I (BACEl), Presenilin-1 (PSENI) and disintegrin
and metalloprotcinase-10 (ADAMlO). Recent studies postulate a correlation between
amyloidogenic processing of APP and infection of neuronal cells by bacteria or viruses.
Here we examine the ability of Herpes simplex virus type I (HSV-1) and Chlamydia

pneumoniae (Cpn) to modify the expression of BACEI, PSENI, and ADAMI 0 in
infected astrocytes. Knowing how these two pathogens might affect the
neurodegenerative pathway to AP may give us insight into the etiology of Alzheimer
disease.
Methods Astrocytes were infected in vitro with Cpn and/or HSV-1. At 24 and 48 hours
of infection, the expression of ADAMlO, BACEI and PSENl was quantified by RT2 PCR. Data from singly or dually infected cells were compared to uninfected cells. Cpn
and HSV-1 copy numbers were measured by qPCR from the same RNA samples. A
potential effect of infection on AP processing was examined by immunofluorescent
labeling of astrocytes.
Results After 24 hours ofHSV-1 infection, cells had decreased expression of ADAMlO,
BACEl & PSENl, which was significantly more extensive after 48 hours ofHSV-1
infection. In contrast, in cells infected with Cpn for 48 hours, BACE 1 expression was
significantly increased, whereas that of ADAMI 0 and PSENl was unchanged.
Interestingly, concurrent infection with HSV-1 and Cpn lessened the reduction in gene
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expression due to HSV-1 alone. Cpn cDNA copy numbers were significantly increased in
the presence ofHSV-1. HSV-1 cDNA copy numbers were largely unchanged by the
presence ofCpn, however, a decrease in HSV-1 cDNA copy number was detected ifCpn
was added simultaneously with HSV-1. Immunofluorescent labeling revealed increased
labeling of A~ in infected astrocytes relative to uninfected cells.
Conclusions While HSV-1 infection may decrease host cell secretase gene expression,
the presence of Cpn may modulate this effect. The ability of either pathogen alone to
induce changes in the amyloidogenic pathway may be altered during active Cpn and
HSV-1 coinfection.
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INTRODUCTION

1.1 Neurodegenerative Disease: Alzheimer disease
Alzheimer disease (AD) is a common type of dementia seen in the elderly; it is
characterized by initial loss of short-term memory progressing to loss of cognition
function. By 2050 AD prevalence is predicted to triple from 2010 [ 1]. Also as the baby
boomers age, the number of AD patients will dramatically increase. There are two
general forms of AD, familial and sporadic. Familial AD, or early onset AD (EOAD), as
its name implies, is dependent on genetics and usually affects a younger population,
while the cause of sporadic AD, or late onset AD (LOAD), is unknown and it affects
older patients. The majority of AD cases are LOAD, hence determining the mechanism
and cause of this form of AD is gravely important. Furthermore, understanding potential
triggers of LOAD may provide insight into how best to diagnose and treat this
progressive neurodegenerative illness.

1.2 Alzheimer disease pathophysiology
The hallmarks of AD are neurofibrillary tangles (NFTs) and amyloid plaques [2].
The aggregates ofNFTs and amyloid plaques correlate with the loss of neurons in the
amygdala and hippocampus, two critical locations for memory processing [3]. NFTs are
composed of hyperphosphorylated tau proteins, which are normally used for stabilizing
microtubules in neurons. When these proteins are hyperphosphorylated, they lose their
solubility and tend to aggregate forming NFTs [4].
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Amyloid plaques are aggregates of a peptide called amyloid-beta (Ap). AP is
derived from proteolytic processing of amyloid precursor protein (APP), a cellular
transmembrane protein. APP is internalized through c!athrin/raft-mediated endocytosis
and is processed by secretases in endosomes [5]. As illustrated in Figure I.I, there are
two postulated pathways for the cleavage of APP: the non-amyloidogenic pathway and
the amyloidogenic pathway [6].
The non-amyloidogenic pathway involves an a-secretase named ADAMIO, which
belongs to a disintegrin and metalloprotease family of proteases [7]. ADAMI 0 cleaves
within the AP cleavage site, causing secretion of a soluble large N-terminal ectodomain
named soluble APP a (sAPPa); the remaining portion of APP attached to the membrane
is the carboxyl terminus end called C88 [8]. Then y-secretase, whose catalytic domain is
named presenilin I (PSENI ), cleaves at amino acid residue C83 creating a nontoxic
protein named P3 and an intracellular protein named APP intracellular domain fragment
(AICD) [9, 10]. AICD is a known to activate promoters for neprilysin and glycogen
synthase kinase 3P (gsk3P) [11].
The amyloidogenic pathway involves a P-secretase, P-site APP cleaving enzyme
(BACE 1) that is usually found in endosomes [9]. BACE I cleaves APP within the lumen
ofthe endosome, resulting in the secretion of soluble APP p (sAPPP) through exocytosis
and a membrane bound carboxyl terminal fragment 99 amino acids long named C99.
PSENl then cleaves C99 in the membrane of the endosome releasing AICD and various
sized AP peptides, most commonly AP
site [9, 10, 12]. AP

(1-42)

(J.40)

or AP

(1-42),

depending on the exact cleavage

is more prevalent in plaques due to its decreased solubility

compared to AP (1-40), which enhances its capacity to aggregate [13]. This amyloidgenic
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pathway culminates in A~ being released extracellularly where it can aggregate to form
the amyloid plaques seen in AD.
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Figure 1.1 APP Processing Pathways.
The left-sided pathway shown is the non-amyloidogenic pathway involving an a-secretase
(ADAMI 0) and a.y-secretase (PSENI) leading to the production of soluble APP fragments. The
right-sided pathway is the amyloidogenic pathway leading to the production of neurotoxic Pamyloid through cleavage mediated by a P-secretase (BACEI) and PSENI.
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1.3 Alzheimer's Disease and apoE
A potential trigger for AD is linked to an apolipoprotein E gene (apoE) isotype.
This gene fimctions in both the central nervous system (CNS) and the vascular system as
a lipid carrier. ApoE is predominantly produced by astrocytes and is essential for myelin
sheath production and repair in mature neurons [14]. There are multiple different isotypes
of apoE, with apoE allele type E4 (apoEE4) being associated with AD, atherosclerosis,
and susceptibility to certain infections [15, 16]. The presence of this gene will increase
the incidence and the onset of AD [ 17].
Research has shown that apoEE4 is involved with AP metabolism by influencing
the aggregation and clearance of AP [15, 18]. APOEE4 has been shown to have a
decelerated clearance of AP when compared to the other isotypes in vivo, however there
is little impact in the rates of AP processing among the isotypes of apoE [19]. The
mechanism of apoEE4 causing a decline in clearance could be due to the weaker binding
of AP to apoEE4 than the other isotypes, thereby causing a lower rate of clearance.
Degradation of AP occurs with neprilysin and insulin degrading enzyme (IDE); these
enzymes are increased in the presence of apoE, however with apoEE4 there could be an
inhibition or decrease of these enzymes causing AP accumulation [18]. Additionally,
apoEE4 has been correlated with increased susceptibility to AP-induced oxidative damage
[ 16]. Also, when compared to the different apoE isotypes, apoEE4 has been linked to a
diminished immune defense mechanisms in the presence of bacteria and viruses [16].
Therefore the additive effects of decreased clearance of pathogens and AP causes
APOEE4 allele to be known as a risk factor for AD.
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1.4 P-site APP cleaving enzyme 1 (BACEl)

BACE 1 expression is prevalent in the nervous system, more commonly found in
neurons compared to other cell types [20]. This protease goes through significant posttranscriptional modifications, first synthesized as a zymogen where it is cleaved in the
endoplasmic reticulum, following folding with cross linking at the catalytic domain [21].
BACEl is located in endosomes and trans-golgi network, however it needs to be
internalized from the plasma membrane in order to cleave APP, and then degraded in
lysosomes [22]. BACEl activity is optimal at an acidic pH and this secretase localizes to
early endosomes where it encounters and cleaves APP [5]. Normally, a miniscule
amount of APP is processed by BACEl however it has been shown in the presence of
high concentration of intracellular cholesterol lead to an increased production of Ap,
allowing the speculation that BACEl activity is heightened in a lipid rich environment
[23]. Increase in apoEE4 or abnormalities oflipid production could influence the
internalization or activity ofBACEl therefore causing the accumulation of Ap.
Since BACEl expression and activity is associated with AP accumulation, which
is a key component of AD pathology, there is interest in using BACE I inhibitors as
therapeutic agents in AD [20]. However, processing of various substrates by BACE 1 has
been implicated in the regulation of axonal myelination, synaptic function, axon guidance
and neurogenesis [21, 24]. Thus, because of the multiple functions ofBACEl in addition
to APP processing, the use ofBACEl inhibitors to manage AD needs to be closely
monitored [21, 24]. BACE I expression has been shown to increase dming hypoxia and
oxidative stress [23], which can be caused by pathogens during chronic infections.
Additionally, inflammation and metabolic stress can manipulate translation ofBACEl
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[25]. Overall, BACEI is a prerequisite for A~ production and aggregation and potentially
a key player in explaining how pathogens, such as HSV-1 and Cpn, can play a role in the
etiology of AD.

1.5 Presenilin (PSEN)

Mutations in presenilin 1 (PSENl ), presenilin 2 (PSEN2) and APP genes are the
most common cause of familial AD [26]. PSENl and PSEN2 are the catalytic domains of
y secretase, a multi-subunit protein complex composed of PSENl or PSEN2, nicastrin,
anterior pharynx -1, and PSENl enhancer-2, all of which are required for enzymatic
activity [27]. Interestingly, PSENl can function as a regulator in the maturation of
BACEl [9]. As with BACEl, there are multiple substrates that can be cleaved by ysecretases in addition to APP, an important one being Notch, a signaling protein involved
in cell differentiation. Disruption of Notch signaling has been associated not only with
abnormalities in development, but also with some cancers and dysregulated T and B
lymphocyte differentiation [28, 29]. Therefore inhibition of PSENI activity to minimize
production of A~ could potentially have adverse consequences unless inhibition was
specific for APP processing.

1.6 A Disintegrin and Metalloprotease-10 (ADAMlO)

ADAMlO is an important member ofa disintegrin and metalloprotease family of
proteins. These proteases, along with BACE proteases, are called "sheddases" because
they cleave membrane-bound substrates to release an ectodomain. The C-terminal
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domain may subsequently undergo additional proteolytic processing, referred to as
regulated intramembrane proteolysis (RIP), by proteases such as y-secretases [30]. This is
the process involved in the non-amyloidgenic pathway of APP processing described
above, which consists of sequential ADAMI 0 and y-secretase cleavage events. While
ADAMIO activity does not cause of the production of toxic AP fragments, a decrease in
ADAMI 0 activity can lead to an accumulation of Ap. As with the P- and y-secretases,
ADAMlO can cleave many substrates, including synaptic proteins. Therefore loss of
ADAMI 0 activity disrnpts the structure and function of synapses. In addition, ADAMI 0
activity releases the Notch ectodomain, allowing y-secretase to activate Notch signaling
through RIP [8, 30]. Thus both ADAMlO and PSENI activity are required for normal
brain development and function mediated by Notch signaling pathways.

1.7 Pathogens and Neurodegenerative Disease
Recent studies on AD focus on how inflanunation can increase the amyloidogenic
pathway. Studies have shown that infectious burden attributed to multiple pathogens
correlates with significantly elevated levels of inflanunatory cytokines and serum Ap, as
well as with AD and higher levels of impaired cognition [3 I]. Chronic activation of the
immune system can cause dysregulation of the blood brain barrier, allowing
autoantibodies to enter the CNS and activate glial cells thereby causing more disruption
in the brain [32]. It has been postulated that infectious agents, such as Chlamydia
pneumoniae (Cpn) and Herpes simplex virus type I (HSV-1), play a role in the etiology
of AD [33, 34]. In autopsied brains of AD patients, DNA and protein specific for Cpn
were detected where AD pathology is observed in the brain [35, 36]. Other studies have
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shown an increase in the production of AP in the brains of mice infected with HSV-1
[37], as well as HSV-1 DNA associated with amyloid plaques [38]. Therefore,
understanding the mechanisms of Cpn and HSV-1 on the amlyoidgenic pathway will
bring insight on the pathology of AD.

1.8 Chlamydia pneumoniae
Chlamydia pneumoniae (Cpn) is an obligate intracellular bacterium typically
considered a respiratory pathogen causing chronic puhnonary infections, but also
postulated to play a role in atherosclerosis [39, 40]. In addition, this bacterium has been
detected in the central nervous system (CNS) of patients with AD [41 ]; an investigation
by Macintyre et al. [42] suggests that Cpn can enter the CNS by transmigrating through
brain endothelial cells within infected monocytes. Cpn reside in astrocytes and microglia
cells in the CNS [ 17].
Cpn has a biphasic life cycle (Figure 1.2) consisting of an elementary body (EB)
that is infectious, though, metabolically inactive, and a reticulate body (RB) that is
noninfectious but metabolically active [43]. EBs are typically found extracellularly and
taken into the host cell through endocytosis after binding to heparin sulfate receptors on
the host cell [44]. Once in the cell's endosome, EBs convert into RBs that will then
multiply through binary fission. Using nutrients and energy provided by the host cell,
RBs produce EBs that are released through endocytosis or cell lysis. When the cell is
stressed, Cpn may go into persistence, whereby RBs form an aberrant body [4 3]. In this
alternate state, Cpn conversion from RB to EB ceases and metabolism is reduced, though
DNA continues to replicate.
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Infectious burden from Cpn has been shown with increased serum levels of AP in
AD and healthy control patients [31]. This could be due to the theory that AP has
antimicrobial properties therefore accumulation of AP is a defense mechanism towards
Cpn [45]. Also, the increased AD risk associated with the apoEE4 allele could be linked
to Cpn by the observation that apoEs4 favors the attachment of EB to host cells compared
to other apoE isotypes, thereby potentially augmenting Cpn infection [46].
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Figure 1.2
Chlamydia pneumoniae life cycle.
The EB form enters the host cell and is converted to an RB, proceeding to multiply and
eventually produce EBs. Once the host cell lysis occurs, EBs are released to start infecting other
host cells. When certain stressors are present Cpn can enter a phase of persistence. Schematic
modified from [43]
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1.9 Herpes Simplex Virus Type 1
HSV-1 is a DNA virus that belongs to the Alphaherpesvirinae subfamily; it is
ubiquitous and known to cause labial sores as well as sporadic cases of viral encephalitis.
HSV-1 can become latent and persist life-long in the trigeminal ganglion with periodic
episodes of reactivation of productive infection. The spread of HSV-1 occurs following
contact with a person who is productively infected and shedding the virus.
Primary infection is limited to about 10 to 14 days depending on the host's
immune system [47]. Envelope glycoproteins B, C, and D ofHSV-1 initiate entry into a
host cell by binding to host cell receptors such as heparin sulfate and nectin [48, 49].
After the virus has entered into the host cell through receptor-mediated endocytosis, the
viral capsid will migrate to the nucleus and release its DNA across the nuclear
membrane. As HSV-1 replicates, it expresses proteins that promote transcription and
translation of viral genes and shut dowu host protein synthesis. Following both protein
synthesis of viral structural proteins and replication of the viral genome, progeny virions
will assemble, pass through the nuclear membrane, bud into the trans-golgi network
where they acquire envelope glycoproteins, and finally exit the cell through exocytosis
[50]. The virus will utilize actin as a mechanism to travel and grow throughout the host
cell. HSV-1 is known to use microtubules for transportation to the nucleus in order to
replicate [51, 52].
While a productive HSV-1 infection takes place in epithelial cells, viral particles
travel via retrograde axonal transport to the trigerninal ganglion where the virus
establishes latency. Once the virus is reactivated it will travel back dowu to the epithelial
cell. He1pes simplex encephalitis (HSE) can occur if there is a chronic infection of HSV-
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1 mainly infecting the temporal lobe. The vims in its latent phase was detected in the
hippocampus and temporal lobe in AD patients [53].
Studies have speculated how HSV-1 can play a role in AD pathology by
influencing the production of tau phosphorylation via augmenting kinases such as gsk3p
or attenuating phosphatases [54]. Also, viral proteins of HSV-1 are homologous to
proteins of Ap, therefore producing auto-antibodies that could have an effect on Ap [32].
Other ways that HSV-1 may have a role in AD is via apoEs4. It has been shown that
HSV-1 is a risk factor for AD in individuals that carry the apoEs4 allele [55-57] and that
in an animal model, mice expressing apoEs4 develop a higher HSV-1 load in their brain
than mice expressing apo&3 [58]. This could be because heparin sulfate proteoglycan is
used by apoE and HSV-1 for entry into cells and perhaps HSV-1 outcompetes apoEs4 for
binding to the receptor, increasing the chances ofHSV-1 infecting host cells [ 56].
Moreover, Burgos et al. [59] speculated that HSV-1 could be using apoE as a mode of
transportation for hematogenous routes of infections. Bullido et al. report that apoEs4
carriers with polymorphisms of the transporter associated with antigen presentation
(TAP) are at an increased risk of AD and speculate that these changes could affect the
host immune response to HSV-1 infection [60]. This idea is supported by an investigation
indicating that the HSV-1 protein that inhibits TAP activity influences neuroinvasiveness
of the virus [61]. Associations between HSV-1 and known risk factors for AD, namely
apoEs4 and TAP, increase the likelihood that HSV-1 plays a role in the etiology or
pathology of AD.
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1.10 Coinfection of Chlamydia pneumoniae and Herpes simplex virns type 1
Infectious burden from pathogens can serve as a risk factor for AD. Overall there
are multiple investigations published showing a possible role for Cpn and HSV-1,
individually, in triggering events that lead to AD [33, 34]. Both pathogens are common in
the elderly and once infected an individual can remain infected indefinitely, therefore
there is a high likelihood of having concurrent infections ofHSV-1 and Cpn. It is known
that both pathogens find entry into the host cells by binding to heparin sulfate
proteoglycans, [44, 48] therefore both pathogens may have an effect on each other.
Previous studies in our laboratory have suggested that in terms of replication, HSV-1 can
have an effect on Cpn and vice versa. This investigation addresses whether the two
pathogens affect the processing of APP, perhaps by altering the activity of the secretases
involved in APP cleavage, and how dual infections with Cpn and HSV-1 may modify the
effects observed with a single pathogen.

1.11 Specific Aims
There are two primary aims of this project. First is to analyze changes in
expression ofBACEl, PSENI, and ADAMIO genes using RT2 -PCR on cDNA derived
from astrocytes infected with Chlamydia pneumoniae and/or HSV-1 for 24 or 48 hours.
Gaining knowledge on how these pathogens affect astrocytes will give us insight on how
these pathogens are involved with neurodegenerative diseases. A second aim is to better
understand how Chlamydia pneumoniae and HSV-1 affect the life cycle of one another in
dually infected cells.

14
1.12 Hypothesis
We postulated that dual infections of astrocytes by HSV-1 and Chlamydia
pneumoniae alters gene expression of secretase genes to a greater extent than that seen
with either pathogen alone, resulting in increased processing of amyloid precursor protein
into Ap. Also, we hypothesized that replication ofHSV-1 would affect Chlamydia
pneumoniae replication to a greater extent than vice versa in dually infected cells.
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METHODS

2.1 Cell lines

STGGl, a human astrocyte cell line (ATCC; CRL-1718), was maintained in
RPMI-1640 (ATCC) containing 10% heat inactivated fetal bovine serum (RPMI-FBS)
(Coming Life Sciences) and cultured at 37°C in 5% COi. Cells destined for infection
were passaged at approximately 85% confluency.
Vero cells (ATCC;CCL-81), an African green monkey kidney cell line, were used
for HSV-1 plaque assays. Vero cells are commonly used for measuring viral replication.
They were propagated in Eagle's minimum essential media (EMEM) with 10% HI-PBS
at 37°C in 5% C02.

2.2 Infection of astrocytes

STTG 1 monolayers were grown for 2 days in 12-well plates seeded at 5xl 05 per
mL ofRPMI-FBS, at which point the mean cell count from 2 wells was determined using
the Countess Automated Cell Counter protocol (lnvitrogen). Cells were infected with
Cpn (respiratory strain AR39; ATCC 53592) and/or HSV-1 (Macintyre strain; ATCC;
VR-539D) at a multiplicity of infection of0.5 and 0.02, respectively. The ATCC Cpn
stock was considered to have 5 x 104 infectious units per 20 µL, while the HSV-1 stock
contained 8 x 10 5 plaque forming units per mL as determined by plaque assay. To
inoculate cells, media was removed from the wells and the appropriate amount of Cpn
and/or HSV-1 in RPMI-FBS was added in a final volume of200 µL. After a 1 hour
incubation period at 37°C to allow the pathogens to attach to the astrocytes, the volume
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was adjusted to 1 mL and cells were incubated for a total of24 or 48 hours. Uninfected
cells were treated similarly and harvested at 24 and 48 hours post inoculation (hpi). For
coinfected monolayers, Cpn and HSV-1 were either added simultaneously or infections
were staggered. The second pathogen was added to staggered coinfections at 24 hpi by
removing-800 mL RPMl-FBS and storing it at 37°C. The second pathogen was added to
the remaining media on the cell monolayer (200 µL final volume) and incubated at 37°C
for an hour, then the 800 mL of stored media was placed back into their designated wells
for the remaining 24 hours (Figure 2.1 ).
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Experimental Design for astrocyte coinfections
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Figure 2.1. Experimental Design for astrocyte coinfections.
A depiction of the times of HSV-1 and/or Cpn infection for the eight experimental groups.
Uninfected cells were harvested at 24 and 48 hpi. Each of the uninfected and infected samples
were obtained in triplicate for each coinfection.
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2.3 Generating RNA lysates
RNA was extracted from astrocytes using Qiagen's RNeasy Kit (Qiagen)
following the manufacturers recommended protocol. The wells were first washed with I
mL of Hank's Balanced Salt Solution (HBSS) without calcium and magnesium, then 300
µL of the RLT lysis buffer from the RNA isolation kit was added to the wells. The

samples were stored at

-80°C until further extraction. Once the lysates were thawed,

they were placed overtop the Qiashredder colunm (Qiagen) and centrifuged at 8,000 xg
for 2 minutes. The flow-through was mixed with 350 µL of70% ethanol and placed on
an RNeasy spin colunm. Additional steps were taken to ensure complete DNA removal
using the RNase-Free DNase Kit (Qiagen) and its recommended protocol. After the
completion of the DNase protocol, Qiagen's protocol for the "Purification of total RNA
from animal cells using spin teclmology'' was followed; RNA was eluted into 30 µL of
RNase-free water. The optical density was measured for each sample to determine the
concentration of RNA and its purification using the Thermo Scientific's NanoDrop 2000c
UV-Vis Spectrophotometer at 260/.,, 280/.,, and 230/.,. Samples were then stored in -80°C
until needed.

2.4 Generating cDNA from mRNA
RNA (IOOng) was converted into cDNA using Ambion's RETROscript kit (Life
Technologies). In a 0.2 mL sterile PCR tube, IOOng of RNA was combined with 3 µL of
random decamers and brought up to 18 µL using nuclease-free water. The mixture was
spun for 5 seconds at 11,000 rpm in a Spectrafuge l 6M microcentrifuge (Denville
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Scientific) after being flicked to ensure proper mixing. Samples were placed in the
Techne TC 3000G Thermocycler (Fisher Scientific) and denatured at 80°C for 3 minutes,
then held on ice before addition of the reverse transcriptase master mix. The master mix
contained 3 µL of !Ox RT buffer, 6 µL of dNTP mix, 0.75 µL ofRNase inhibitor, 0.75 µL
ofMMLV Reverse Transcriptase and 1.5 µL of nuclease free water per RNA sample; 12

µL of this master mix was added to each RNA/random primer sample for a total volume
of 30 µL. The mixture was then placed in the Techne TC 3000G Thermocycler and
incubated at 43°C for I hour, followed by 92°C for 10 minutes to inactivate the reverse
transcriptase. Samples were then stored at -20°C.

2.5 RT 2-PCR for ADAMlO, BACE1, PSEN1, and actin gene expression
Gene expression of ADAMIO, BACEI, PSENI and actin was quantified using
Taqman gene expression system (Applied Biosystems) in a multiplex set up with 18s
rRNA as endogenous control. A primer master mix was assembled using I 0 µL of 2x
Taqman gene expression master mix, I µL of l 8s rRNA primer limiting primer, and I µL
of the experimental primer (ADAMI 0, BACEI, PSENI or actin) per well. All primers
were obtained from Thermofisher. Thirty microliters of the sample cDNA was combined
with 75 µL of nuclease free water to make a sample master mix with a total volume of
I 05 µL; each master mix was pipetted up and down to ensure a homogenous suspension.
Twenty-five microliters of the sample master mix was combined with 37 µL of the
designated primer master mix. This final mixture was mixed by flicking and was
centrifuged for 5 seconds at 11,000 rpm in a Spectrafuge 16M microcentrifuge (Denville
Scientific). A total of 20 µL of the final mixture was pipetted into the designated well in
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triplicate. Once all the samples were loaded into 96-well plate (Thermofisher), they were
sealed and capped with cap strips (Thermofisher). RT-PCR was performed using an
Applied.Biosystems StepOne Plus RT-PCR instrument. The cycling protocol is depicted
in Table 2.1 for 40 cycles. The Thermofisher Cloud Software
(https://apps.thermofisher.com/apps/spa/#/dashboard; Relative RQ Application) was used
to analyze the amplification data received from the StepOne Plus.

Table 2.1.

Cycling Protocol for RT-PCR

Holding Stage

95°C for 10 minutes
95°C for 15 seconds

Cycling Stage
60°C for I minute

2.6 Quantification of HSV-1 and Chlamydia pneumoniae copy numbers
HSV-1 and Cpn copy numbers were measured in cDNA samples by RT-PCR
using Cpn- and HSV-1-specific primers from Primer Design (Gensig). A primer master
mix was assembled using 40 µL Taqman gene expression master mix, 4 µL ofHSV-1 or
Cpn primer and 22 µL of nuclease water, which generates 6 µL extra reaction mixture to
account for pipette variability. The primer master mix was pipetted up and down to and
then split into 0.2mL sterile PCR tubes. Twenty microliters of cDNA generated from
100 ng of RNA as described above was added to the PCR tube containing the primer
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master mix and homogenized again by pipetting up and down. Twenty micro liters of the
final mixture was then pipetted into designated wells in quadruplicate, with each well
containing cDNA derived from 25 ng of RNA. Standard curves for determining Cpn and
HSV-1 copy number were set up similarly to experimental samples, substituting 5
µUwell diluted standards provided by Gensig for sample cDNA. Samples and standards
were amplified as described above except that during the cycling stage the plates was
held at 95°C for 10 seconds instead of 15 seconds; data was analyzed using the
Thermofisher Cloud Software (https://apps. thermofisher.corn/apps/spa/#/dashboard;
Standard Curve Application).

2.7 Immunofluorescence
Astrocytes were infected in 12-well plates containing glass coverslips (GG-121.5-pre, Neuvitro). Once the infection was complete, coverslips were placed in a new 12well plate with 1 mL ofHBSS in each well. HBSS was removed and 500 µL of
Cytofix/Cytoperm Buffer (Invitrogen) added for 30 minutes. Samples were washed with
1 mL phosphate-buffered saline (PBS) twice. Thirty minutes of incubation at room
temperature (25°C) with 1 mL of Ix Permwash (Thermofisher) was used to block the
samples. Cells were then incubated at 4 °C overnight with primary antibodies diluted to
the desired concentration (Table 2.2) with 1x Permwash. The appropriate secondary
antibody, diluted in 1x Permwash, was added to the samples maintained above a 3 7°C
water bath for 2 hours. Coverslips were inverted and mounted on microscope slides with
10 µL offlurogel II mounting media containing DAPI (17985-50, Electron Microscopy
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Sciences). Images were taken either on an epi-fluorescent scope (Nikon Eclipse 90i) or
on Olympus FVl 000 Confocal microscope.

Table 2.2.

Primary and secondary antibodies used for immunofluorescence

Primary Antibody

Secondary Antibody

T96

HSV-1

Thermofisher,
MAl-19267

594 Anti-mouse
1:1000

Molecular
Probe, A-11029

1:1000

-

1:200

-

1:500

FITC conjugated
Fitzgerald,
60C-CR2124RF
FITC conjugated
Cpn

Fitzgerald,
61C75A
6El0

Amyloid

BioLegend,
SIG-39320

555 Anti-mouse
1:200

Synaptic Systems,
218-703

1:200

BioLegend,
SIG-39148

1:1000

Abeam,
Abl0716

1:200

Molecular
Probe, A-11034

1:1000

488 Anti-rabbit

BACEl
BACEl

Molecular
Probe, A-11037
488 Anti-rabbit

Poly8119
AICD

1:200

594 Anti-rabbit

AP42
Amyloid p 1-42

Molecular
Probe, A32727

1:1000
.

Molecular
Probe, A-11034

1:500
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2.8 Statistical analysis

The Thermofisher Cloud Software for analyzing gene expression
(https://www.thermofisher.com/us/en/home/digital-science.html) utilizes a two-tailed
Student's T-test using delta CT values obtained during RT-PCR amplification to
determine the significance between the expressions of host genes in different samples.
The significance between pathogen copy numbers was determined by an analysis of
variance (ANOVA) using the Holm-Sidak method for pairwise multiple comparison. P
values~

0.05 were considered significant.
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RESULTS

3.1 Changes in host cell gene expression in uninfected samples over time
RT2- PCR was used to determine whether there is a change in expression of
ADAMI, BACEl, PSENl and actin following dual and single infections in astrocytes;
18s rRNA was used as the endogenous control. Potential changes in gene expression
were compared to expression in uninfected samples at 24 hours and 48 hours post
infection (hpi). Interestingly, the host gene expression of all 4 genes in uninfected
astrocytes was reduced at 48 hours compared to that at 24 hours (Figure 3.1). BACEl and
actin gene expression in uninfected astrocytes was significantly reduced at 48 hours (pvalues = 0.005 and 0.05, respectively). Consequently, expression of host genes at 24 hpi
was measured relative to 24 hour uninfected samples while that at 48 hpi was measured
relative to 48 hour uninfected samples.

25

1.2

1.0

<:I

.s
"'
""'....

~

"
"<:I
"

0.8

0.6

bl)

.:::"

0.4

1'i

~

0.2

0.0
ADAMlO

BACEl

11124 hr uillnfected

Figure 3.L

PSENl
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• 48 hr uninfected

Expression of ADAMlO, BACEl, PSENl, and actin by astrocytes in uninfected
samples at 24 hours and 48 hours.
Equal volumes of cDNA generated from reverse transcription of equal amounts of RNA derived
from uninfected astrocytes were amplified by quantitative PCR using 18s rRNA as the
endogenous control to normalize samples. Shown is the mean relative gene expression derived
from 3 separate infections performed in triplicate (n=9) and expressed relative to 24 hour
uninfected cells; error bars represent the 95% confidence interval.
• BACEl (p = 0.005) and actin (p = 0.05) expression was significantly reduced in 48 hour
uninfected cells as compared to that of 24 hour uninfected cells.
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3.2 Changes in host gene expression at 24 hours post infection
Relative expression of ADAMl, BACEl, PSENl, and actin following 24 hours of
single or dual infection with HSV-1 and/or Cpn is shown in Figure 3.2. Reduction in
expression of ADAM 10 and BACEl in astrocytes infected with HSV-1 for 24 hours
approached significance with p-values of 0.06 and 0.07, respectively, while the reduction
in expression of PSENl in these samples was significant (p = 0.02). Although there was
a reduction in ADAMIO, BACEl, and PSENl mRNA levels in astrocytes infected with
HSV-1for24 hours, there was no significant change in actin rnRNA levels following 24
hours of infection with HSV-1. Astrocytes infected with Cpn alone or a 24 hour
coinfection with simultaneous inoculation of HSV-1 and Cpn (HSV-1/Cpn 24/24 hpi),
showed no significance difference in expression of all 4 genes compared to uninfected
samples.
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Figure 3.2.

Expression of ADAMlO, BACEl, PSENl and actin by astrocytes in the presence
or absence of HSV-1 and/or Chlamydia pneumoniae at 24 hours post infection.
Equal volumes of cDNA generated from reverse transcription of equal amounts of RNA derived
from infected and uninfected astrocytes were amplified by quantitative PCR using 18s rRNA as
the endogenous control to normalize samples. Shown is the mean relative gene expression
derived from 3 separate infections performed in triplicate (n=9) and expressed relative to 24 hour
uninfected cells; error bars represent the 95% confidence interval.
* Difference in gene expression in samples of 24 hour HSV-1 infected cells relative to 24 hour
uninfected cells approached significance for ADAMlO (p = 0.06) and BACEl (p = 0.07).
**Gene expression of PSENl in 24 hour HSV-1 infected cells was significantly reduced
compared to that of24 hour uninfected cells (p = 0.02).
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3.3 Changes in host gene expression at 48 hours post infection
Relative expression of ADAMl, BACEl, PSENl, and actin following 48 hours of
single or dual infection with HSV-1 and/or Cpn is shown in Figure 3.3. In addition to
simultaneous inoculation ofHSV-1 and Cpn (HSV-1/Cpn 48/48 hpi), coinfections were
also staggered so that cells were inoculated with the second pathogen at 24 hpi (HSV1/Cpn 24/48 hpi and HSV-1/Cpn 48/24 hpi), which would give the first pathogen time to
establish an infection before addition of the second pathogen. All cells infected with
HSV-1for48 hours showed a dramatic reduction in gene expression of ADAMlO,
BACE l, PSENl, and actin relative to that of uninfected cells. When comparing 48 hour
infections with HSV-1 alone to 48 hour simultaneous dual infections with HSV-1 and
Cpn (HSV-1/Cpn 48/48 hpi), the coinfection showed an increase in gene expression in all
4 genes with p-values <0.01.
Astrocytes infected with Cpn alone for 48 hours did not show any changes in gene
expression when compared to uninfected cells except for BACE 1, which was
significantly increased (p-value = 0.02). Gene expression observed in staggered
infections was dependent upon whichever pathogen was present for 48 hours; the
addition of the second pathogen at 24 hpi had little effect on ADAMI, BACEl, PSENl,
or actin gene expression with the exception ofBACEl expression in HSV-1/Cpn 24/48
hpi samples. In these samples, the increase in BACEl expression seen at 48 hpi with Cpn
was not observed when HSV-1 was added 24 hours after inoculation with Cpn.
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BACEl

PSENl

ACTIN
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•Cpn 48 hpi

•HSV-1 48 hpi

• HSV-1/Cpn 48/48 hpi

iii HSV-1/Cpn 24/48 hpi

• HSV-1/Cpn 48/24 hpi

Expression of ADAMlO, BACEl, PSENl and actin by astrocytes in the presence
or absence ofHSV-1 and/or Chlamydia pneumoniae at 48 hours post infection.
Equal volumes of cDNA generated from reverse transcription of equal amounts of RNA derived
from infected and uninfected astrocytes were amplified by quantitative PCR using l 8s rRNA as
the endogenous control to normalize samples. Shown is the mean relative gene expression
derived from 3 separate infections performed in triplicate (n=9) and expressed relative to 48 hour
uninfected cells; error bars represent the 95% confidence interval.
*Gene expression in cells infected simultaneously for 48 hours with HSV-1 and Cpn (HSV-1/Cpn
48/48 hpi) was significantly greater than that of cells infected for 48 hours with HSV-1 alone (p
<0.01).
** BACEl gene expression in 48 hour Cpn-infected cells was significantly increased relative to
that of 48 hour uninfected cells (p = 0.02).
***The reduction in actin gene expression between cells dually infected with HSV-1 for 24
hours and Cpn for 48 hrs (HSV-1/Cpn 24/48 hpi) relative to 48 hour uninfected cells approached
significance (p = 0.06).
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3.4 Quantification of HSV-1 and Chlamydia pneumoniae copy numbers
To assess whether HSV-1 can intenupt the life cycle of Cpn and if Cpn can affect
HSV-1 replication, RT2 -PCR was used to quantifyHSV-1 and Cpn copy numbers from
cDNA. As would be expected, the infectious burden was substantially higher at 48 hours
of infection compared to 24 hours of infection in astrocytes infected with HSV-1 (Figure
3.4). However, a significant decrease in HSV-1 copy number was observed in cells
simultaneously coinfected with HSV-1 and Cpn for 24 hours (HSV-1/Cpn 24/24 hpi)
compared to cells infected with HSV-1 alone for 24 hours. This can also be said when
compared to staggered coinfections where cells were initially infected with Cpn, then
inoculated with HSV-1 at 24 hpi (HSV-1/Cpn 24/48 hpi). On the other hand, following
dual infections where HSV-1 was present for 48 hours and Cpn for either 48 (HSV/Cpn
48/48 hpi) or 24 (HSV-1/Cpn 48/24 hpi) hours, HSV-1 copy numbers were similar to that
derived from 48 hour HSV-1 infections.
As seen in Figure 3.5, astrocytes infected with Cpn alone, had a higher infectious
burden at 24 hpi than 48 hpi. Interestingly, when comparing single and dual infections,
the presence of HSV-1 was associated with an increase in Cpn copy number relative to
that measured in cells infected with Cpn alone.
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Figure 3 .4.

HSV-1 copy number quantified in astrocytes in the presence and absence of
Chlamydia pneumoniae.
HSV-1 copy numbers were measured in cDNA derived from 3 infections performed in triplicate
(n=9); error bars represent the standard error of the mean.
* All 48 hour single and dual HSV-1 infected monolayers had significantly higher copy numbers
relative to those of24 hour single and dual infections (p<0.001), however copy numbers from all
HSV-1 48 hour monolayers were not different from each other.
** Copy numbers from cells dually infected with HSV-1 and Cpn for 24 hours (HSV-1/Cpn
24/24 hpi) were significantly reduced relative to that observed in both HSV-1 24 hour single
infections (p = 0.007) and in dually infected cells exposed to HSV-1 for 24 hours and Cpn for 48
hours (HSV-1/Cpn 24/48 hpi; p = 0.012).
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Figure 3.5.

Chlamydia pneumoniae copy number quantified in astrocytes in the presence and
absence of HSV- L
Cpn copy numbers were measured in cDNA derived from 3 infections performed in triplicate
(n=9); error bars represent the standard error of the mean.
* Cpn copy numbers from monolayers infected with Cpn for 24 hours were significantly different
from those of cells infected simultaneously with HSV-1 and Cpn for 24 hours (HSV-1/Cpn 24124
hpi; p<0.001) and from dually infected cells exposed to Cpn for 24 hours and HSV-1 for 48 hours
(HSV-1/Cpn 48124 hpi; p = 0.014) samples.
** Copy numbers from monolayers infected with Cpn for 48 hours were significantly different
from those of cells simultaneously infected with Cpn and HSV-1for48 hours (HSV-1/Cpn 48148
hpi; p = 0.009) and staggered coinfections where cells were exposed to Cpn for 48 hours and
HSV-1 for 24 hours (HSV-1/Cpn 24148 hpi; p = 0.01 ).
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3.5 Qualitative assessment of Chlamydia pneumoniae and HSV-1 infection of
astrocytes

For further analysis of how Cpn and HSV-1 can affect each other's infectious
processes, as well as the cells that they infect, a qualitative approach was taken by
immunolabeling HSV-1 and Cpn in infected astrocyte monolayers. Immunofluorescence
revealed that an astrocyte can be infected with Cpn and HSV-1 simultaneously (Figure
3.6). It is common for HSV-1 infected astrocytes to become distorted and have a more
rounded nucleus and to form syncytia, which are large multinucleated cells resulting from
virus-induced cell-to-cell fusion. Syncytia are present in monolayers infected for 48 hour
with HSV-1, and Cpn labeling was observed within the syncytia, indicating that it is
possible for Cpn to infect cells that exhibit cytopathology consistent with viral infections.

3.6 Qualitative assessment of Aj3 infected and uninfected astrocytes

Immunofluorescence labeling was used to qualitatively assess changes in the
protein levels of amyloid in infected astrocytes at 24 and 48 bpi. An antibody reactive to
Aj3 residue 1-16 (6EIO) revealed an increase in the protein level of Aj3 in both Cpn- and
HSV-1-infected cells relative to uninfected cells (Figures 3.7 and 3.8, respectively).
When comparing 24 and 48 hour Cpn infections, it is difficult to determine if a prolonged
infection with Cpn correlates with increased amounts of Aj3. Immunofluorescent
labeling of 24 hour HSV-1 and Cpn dually infected cells revealed more intense labeling
for amyloid compared to uninfected cells, regardless of whether or not the astrocytes
were part of syncytia.
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Figure 3.6.

Immunofluorescent labeling of Chlamydia pneumoniae and HSV-1 in uninfected
and dually infected astrocytes.
Infections included 24 and 48-hour simultaneous inoculation with Cpn, and HSV-1. Cells were
labeled for Cpn (green) and HSV-1 (red); nuclei were labeled with dapi (blue).
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Figure 3.7.

Jmmunofluorescent labeling of AJ3 and Chlamydia pneumoniae in uninfected and
infected astrocytes.
Infection included 24 and 48 hour single infections with Cpn, as well as 24 hour simultaneous
dual infections with Cpn and HSV-1. Cells were labeled for Cpn (green) aod amyloid (red);
nuclei were labeled with dapi (blue).
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Figure 3.8.

hnmunofluorescent labeling of Ai3 and HSV-1 in uninfected and infected
astrocytes.
Infection included 24-hour single infections with HSV-1, as well as 24-hour simultaneous dual
infections with HSV-1 and Cpn. Cells were labeled for HSV-1 (green) and amyloid (red); nuclei
were labeled with dapi (blue).
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DISCUSSION

4.1 Changes in astrocyte gene expression over time

When comparing uninfected astrocytes at 24 and 48 hours, it was interesting to
note that there was reduced gene expression in all four genes at 48 hours post-infection
(hpi), which was statistically significant for both BACE 1 and actin mRNA. This
difference in host gene expression over time may reflect changes in cellular growth rate,
or other cellular processes, that occurs as the monolayers approach confluency.
Therefore, it was necessary when assessing relative gene expression of infected cells that
the comparison was made to the appropriate uninfected time point.

4.2 Regulated intramembrane proteolysis mediated by a-,

P-, and y-secretases

The processing of APP via both the amyloidgenic and non amyloidgenic
pathways are examples of regulated intramembrane proteolysis, or RIP [29]. In RIP, the

a- or P-secretases initially cleave and release the ectodomain of a transmembrane protein.
The y-secretases further cleave the membrane-associated C-terminal fragment, which can
trigger activation or deactivation of different cell signaling processing, depending on the
transmembrane protein that is being processed. For example, y-secretase cleavage of the
C-terminal fragment of APP following initial ADAMI 0 and particularly BACEl
cleavage releases AICD that returns to the nucleus to modulate gene transcription [62,
63]. An additional important cell-signaling pathway that is activated by the process of
RIP and mediated by ADAMlO & y-secretase is that of Notch. Notch signaling is
involved in many cellular processes including proliferation, differentiation and cell death
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[64]. Therefore, changes in expression of these secrctase genes can potentially contribute
to CNS pathology through different cellular pathways, not just the amyloidgenic
pathway. The diminished ADAMIO and PSENl gene expression observed in the
presence of HSV-1 might disrupt cellular signaling pathways by disrupting Notch
signaling, which could contribute to HSY-I-mediated cytopathology independently of
effects of HSV-1 on APP processing.

4.3 Manipulation of astrocyte gene expression in the presence of Herpes simplex
virus type 1
It is common for gene expression of the host cell to diminish in the presence of a

viral infection. Since HSV-1 manipulates gene expression it was necessary to find a gene
that remains stable during viral infection of astrocytes to use as a housekeeping gene for
quantitative RT-PCR. Earlier work from our lab determined that the cycle thresholds
observed during amplification of cDNA derived from HSV-1-infected astrocytes using
actin- and GAPDH-specific primers change over time, while that observed using 18s
rRNA-specific primers do not. Therefore, when comparing gene expression in uninfected
and infected cells by quantitative RT2-PCR, 18s rRNA was used as the reference gene to
normalize gene expression to cDNA levels.
In astrocytes infected with HSV-1 for 24 hours, there was a reduction in
ADAMlO, BACEl, and PSENI gene expression when compared to uninfected astrocytes
at 24 hpi. Whereas gene expression of the secretase genes was downregulated, that of
actin mRNA remained the same during a 24 hour infection suggesting that the decrease in
secretase gene expression was not just due to generalized suppression of host
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transcription in the present of the virus. It is possible that actin gene expression is
conserved at early times post infection because HSV-1 utilizes actin to help enter target
cells and initiate viral replication [49, 52]. The significant decrease of actin gene
expression at 48 hours compared to 24 hours of infection is consistent with the
observation that actin levels decrease at later stages of HSV-1 infection [52].
The dramatic decrease in expression of the secretase genes seen at 48 hpi may
reflect general viral-mediated shut down of host gene expression as the virus replicates,
however the extent of transcriptional down regulation differed among the secretase genes
and actin. BACEl had the greatest decline in gene expression of the three secretase
genes. One could speculate that cell signaling pathways regulated by P-secretase
processing may be affected to a greater extent than those regulated by u-secretases, which
may perhaps include APP processing. Also, qualitatively we looked at BACEl protein
levels through immunofluorescence of astrocytes at 24 hpi and observed increased
BACEl labeling in HSV-1 infected cells relative to uninfected astrocytes. The decrease
in gene expression for BACEl with HSV-1 infection while observing an increase in
BACEl protein staining can be due to BACEl half-life being long enough such that the
gene expression decline at 24 hpi was not yet evident at the protein level. It would be
interesting to determine how HSV-1 infection affects BACEl protein levels and enzyme
activity over time, as well as relative levels of ADAMIO versus BACEl generated APP
fragments.
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4.4 Manipulation of astrocytes gene expression in the presence of Chlamydia

pneumoniae
When comparing Cpn infected and uninfected astrocytes at 24 hpi, there was no
significant change in ADAMlO, BACEl, PSENl or actin gene expression. This could be
due to Cpn being in a relatively early part of its life cycle where it is still in the phase of
converting from EBs into RBs. One could speculate that there isn't a significant change
in gene expression at 24 hours since Cpn is not fully in its metabolically active form, thus
not yet affecting host gene expression.
While ADAMlO, PSENl and actin gene expression did not significantly change
following a 48 hour infection with Cpn, data indicated a significant increase ofBACEl
gene expression in infected astrocytes at this time point. These results agree with
previous lab studies using an MOI of 1, which also included an analysis of protein levels
and enzymatic activity of BACE 1 at 48 hpi, and demonstrated an increase in both. These
prior results, along with the observed increase in BACEl gene expression from this
study, suggest a potential increase in APP processing, eventually leading to an increase of
amyloid ~ deposits.
It is interesting to note that while BACEl gene expression was increased at 48

hpi, expression of neither PSENl nor ADAM!O genes were significantly different than
uninfected cells at that time point. Perhaps there is an alternate function of BACE 1 that
promotes the infection ofCpn, thereby favoring enhancement of the expression of that
enzyme and not ADAM!O orPSENl. It is not known whether the increase in BACEl
expression observed here is a direct or indirect consequence of Cpn infection.
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4.5 Manipulation of astrocyte gene expression during Chlamydia pneumoniae and
Herpes simplex virus type 1 coinfections
Although infection of astrocytes with HSV-1 alone revealed a decrease in
expression of all three secretase genes by 24 hours, simultaneous infection with both
HSV-1 and Cpn for 24 hours (HSV-1/Cpn 24/24 hpi) resulted in no significant change in
expression of the three secretase genes when compared to uninfected astrocytes.
Similarly, the decrease in gene expression observed in astrocytes infected with HSV-1
alone for 48 hours was lessened in the presence of Cpn during simultaneously inoculated
dual infections (HSV-1/Cpn 48/48 hpi). Once within a host cell, Cpn and HSV-1 would
have different effects on cellular function to allow their respective infections to progress.
Viruses such as HSV-1 tend to take over cellular functions and control transcription,
whereas Cpn replicates within inclusion bodies using cellular energy. Presumably, the
two pathogens would have different requirements for manipulating cellular functions.
Our data suggest that Cpn was able to modify virus-induced. changes in gene expression
to some extent, but not prevent or reverse the HSV-1-induced downregulation of
expression in the genes we examined.
The data indicate that expression ofBACEl by Cpn-infected astrocytes at 48 bpi
increased relative to that seen in 48 hour uninfected cells. However, this increase was
negated in the presence of HSV-1, even when the virus was added 24 hours after Cpn had
established infection (HSV-1/Cpn 24/48 bpi). This could reflect an ability ofHSV-1 to
outcompete Cpn as both pathogens replicate within the same host cell.
Astrocytes that were first infected with HSV-1 and then inoculated with Cpn at 24
bpi (HSV-1/Cpn 48/24 hpi) demonstrated similar levels ofsecretase gene expression as
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seen with HSV-1 alone at 48 hours. By 48 hpi, extensive viral replication had already
occurred; presumably, when Cpn was added, the bacteria was unable to modify HSV-1induced changes in gene expression. OveralL the observation that various levels of gene
expression differ during dual infection of astrocytes compared to single infections
demonstrates how HSV-1 and Cpn have an effect on each other.

4.6 Herpes simplex virus type 1 replication in astrocytes in the presence and absence
of Chlamydia pneumoniae

In addition to assessing the effect of single and dual infections of astrocytes on

secretase gene expression, we also wanted to consider how HSV-1 and Cpn affect each
other's ability to replicate in dually infected astrocytes. Through immunofluorescence it
was revealed that both HSV-1 and Cpn can co-habitate a single astrocyte at 24 hpi and 48
hpi. However, quantitative RT-PCR depicted a competition between the pathogens. At 24
hpi, when Cpn simultaneously infected astrocytes with HSV-1 (HSV-1/Cpn 24/24 hpi)
there was a significant drop in HSV-1 copy numbers. This could reflect competition
between the two pathogens for the same receptor or entry pathway. This competition
would not occur when HSV-1 was added to astrocytes already infected with Cpn
(HSV/Cpn 24/48 hpi) since Cpn would already be internalized, which is consistent with
the data indicating similar copy numbers from HSV-1 24 hour alone infection and
RSV /Cpn 24/48 hpi samples. It is interesting to note that for coinfected cells at 48 hours
ofHSV-1 infection (HSV-1/Cpn 48/48 hpi or HSV-1/Cpn 48/24 hpi) there was no
significant change in copy numbers when compared to 48 hour HSV-1 single infections.
These data may indicate that Cpn inhibits HSV-1 replication by interfering with an early
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step in viral replication, such as attachment or entry; once viral replication increases
exponentially, it overcomes any early inhibition by Cpn.

If HSV-1 and Cpn were to compete for receptors on host cells it would be
consistent with the observation that HSV-2 and Chlamydia trachomatis compete for
binding to nectinl to enable entry into host cells [65]. In addition, Cpn and HSV-1 both
interact with the epithelial growth factor receptor for entry, therefore it is reasonable to
conclude that during dual infections, Cpn and HSV-1 could be in direct competition with
each other to establish infection in host cells [66, 67]. At 24 hpi, ifCpn were to inhibit
HSV-1 replication, it could explain the impaired inhibition of secretase expression in
simultaneously inoculated dual infections (HSV/Cpn 24/24 hpi) compared to single HSV1 infections. However, HSV-1 copy numbers at 48 hpi were similar regardless of the
presence or absence ofCpn. Therefore, the diminished shutdown ofHSV-1-induced host
gene expression observed in 48 hour dual infections (HSV/Cpn 48/48 hpi) cannot be
explained by inhibition of viral replication in the presence of Cpn.

4.7 Chlamydia pneumoniae replication in astrocytes in the presence and absence of
Herpes simplex virus type I
Unlike the HSV-1 copy numbers, as a Cpn infection goes from 24 hours to 48
hours Cpn copy numbers decrease. It is possible that this apparent drop in Cpn copy
numbers is a reflection of the complex life cycle of Cpn. Copy numbers were quantified
by amplification of cDNA using a primer specific for chlamydia ! 6s rRNA and should,
therefore, reflect levels of chlamydia! mRNA. Since RBs are the metabolically active
form of Cpn, higher levels of Cpn mRNA would be expected to be associated with RBs
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than with a similar number ofEBs. Furthermore, RBs are capable of multiplying,
suggesting that higher levels of chlamydia! mRNA would be associated with the stage in
the Cpn life cycle when EBs have largely converted to RBs. At later time points, as RBs
convert back into EBs, chlamydia! mRNA might be expected to decrease. It is possible
that in our infections of astrocytes, at 48 hpi RBs have already converted back into EBs,
or are in the process of doing so, and therefore cDNA-associated copy number could be
dropping.
It is also important to consider that the RT 2 -PCR amplification protocol

normalized RNA levels between samples using a host l 8s rRNA primer. It is possible
that astrocyte cell division allowed host cell mRNA to increase at a rate that was more
rapid than that of Cpn mRNA. This would result in Cpn sequences accounting for a lower
percentage of total mRNA in cell lysates at 48 hpi than at 24 hpi, which could also
explain an apparent drop in Cpn copy number at 48 hpi relative to 24 hpi.
Interestingly, in all dual infections, Cpn copy number was always greater in the
presence ofHSV-1 than that measured in the appropriate single Cpn infection. It is
possible that HSV-1 enhances the Cpn life cycle, perhaps by increasing the rate of
multiplication ofRBs. Alternatively, the virus may somehow prevent the conversion of
RBs back into EBs, thereby resulting in a greater number of cDNA-associated copy
numbers. Interestingly, HSV-2 drives Chlamydia trachomatis into persistence [68],
whereas a similar phenomenon may not occur with HSV-1 and Cpn.
In addition, it is possible that extraction of RNA from Cpn in its EB form may not
be as efficient as RNA extraction from Cpn in its RB form. The increase in Cpn copy
number observed in coinfected cells relative to that of single infections may reflect more
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efficient extraction of Cpn RNA in host cells whose membranes were altered by infection
with HSV-1. HSV-1 infection can cause syncytia formation therefore altering the cell
membrane integrity hence more RNA can be extracted.

4.8 Future Directions

Now that there is data showing that there is a change in gene expression in the
secretases involved in processing APP in the presence ofHSV-1 and/or Cpn, the next
step would be to see if changes in the protein levels parallel changes in gene expression
in infected astrocytes. Western blots could be used to assess protein levels of ADAMIO,
BACEl, and PSENl in single and dual infection ofastrocytes. Although infection of
astrocytes with HSV-1 decreases the transcription of all three secretases, if these enzymes
are relatively stable they may still be able to persist and contribute to the neurological
pathology observed in AD. It would also be interesting to examine earlier time points,
such as 6 bpi and 12 bpi, since we are predicting that HSV-1 and Cpn compete with each
other earlier on in infections.
Using western blots to examine possible changes in AP(l-42) levels in infected
astrocyte lysates and culture supernatants will help clarify whether AP processing is
being altered as a result of single or dual infections and whether it is being secreted out of
the cell. Analysis of the enzymatic activity of ADAMlO, BACEl, and PSENl can also
be conducted on infected astrocyte lysates and would provide information on changes in
APP processing as a result of infection. Therefore, we can examine the whole process
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from gene expression to protein to enzymatic activity in order to gain a clearer
understanding of how A~ is affected by HSV-1 and Cpn infection.
There are other enzymes and proteins involved in APP processing that could be
examined to provide a more complete understanding of the role these pathogens play in
AD pathology. For example, we could address the question of whether HSV-1 or Cpn
alters clearance of A~ by examining the expression and activity of neprilysin, which
plays a role in A~ clearance. It is possible that HSV-1 and/or Cpn play a role in AD
pathology by altering the clearance of A~ as well as the generation of these neurotoxic
fragments.
To investigate further the effect ofHSV-1 and Cpn on each other, we need to
clarify the occurrence and timing of EBs, RBs or persistent forms the Cpn within infected
astrocytes in both the presence and absence of HSV-1. Electron microscopy is currently
the accepted method to identify the different forms of Cpn within a host cell. This
approach would help clarify how HSV-1 may effect the Cpn biphasic life cycle.
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